US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ALPS Medical Breakthroughs ETF

55.04

+1.102.03%

Post-market: 55.040.00000.00%19:30 EDT

Volume:33.64K

Turnover:1.85M

Market Cap:192.64M

PE:- -

High:55.51

Open:54.50

Low:54.37

Close:53.95

52wk High:70.85

52wk Low:40.40

Shares:3.50M

Float Shares:3.50M

Volume Ratio:0.55

T/O Rate:0.96%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Xenon Pharma Grants 32,758 Inducement Stock Options, 19,013 RSUs to New Hires

Xenon Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sector Update: Healthcare

MT Newswires Live

AbbVie Lowers Outlook to Account for Acquisition, as 2Q Profit Jumps

Abbvie Shares Down 3.6% Premarket After Co Cuts 2026 Profit Forecast on Apogee Buy

THOMSON REUTERS

AbbVie Trims 2026 Profit Forecast on Apogee Buy, Beats Second-quarter Estimates

Health Rounds: Experimental Cell Therapy Slows Heart Failure Progression in Duchenne Muscular Dystrophy

Analysts Have Conflicting Sentiments on These Healthcare Companies: Phibro Animal Health (PAHC), Universal Health (UHS) and CG Oncology, Inc. (CGON)

CG Oncology announces publication of BOND-003 results in The Lancet Oncology

CG Oncology Says Phase 3 Bond-003 Data for Cretostimogene in BCG-unresponsive Bladder Cancer Publish in Lancet Oncology

Oppenheimer would own Capricor Therapeutics into committee meeting

CG Oncology Director Leonard Post Disposes of 1,000 Shares for $71,170

Ani Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter

Why Healthcare Stocks Look Like a Haven in This Market

ANI Pharmaceuticals intends to appeal rulings in CG Oncology matter

ANI Pharma Plans Delaware Supreme Court Appeal in CG Oncology Dispute

CG Oncology Director James Mulay Disposes of Common Shares Worth $1.82 Million

Press Release: $hareholder Alert: the M&A Class Action Firm Launches Legal Inquiry for the Merger

CG Oncology (CGON) In Focus Following Early Trial Results And BLA Timing Questions On Value

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/SBIO/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"SBIO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SBIO\",,,,,undefined,":{"symbol":"SBIO","market":"US","secType":"STK","nameCN":"ALPS Medical Breakthroughs ETF","latestPrice":55.04,"timestamp":1791576000000,"preClose":53.945,"halted":0,"volume":33639,"hourTrading":{"tag":"盘后","latestPrice":55.04,"preClose":55.04,"latestTime":"19:30 EDT","volume":20,"amount":1097.9053,"timestamp":1791588605643,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.020298452127166536,"floatShares":3500000,"shares":3500000,"eps":0,"marketStatus":"Market Closed","change":1.095,"latestTime":"10-09 16:00:00 EDT","open":54.5,"high":55.5141,"low":54.365,"amount":1850295.02994,"amplitude":0.021301,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":53.945,"sharesOutstanding":2675000,"nav":53.95,"aum":187460316.33,"bidAskSpread":0.002399,"postHourTrading":{"tag":"盘后","latestPrice":55.04,"preClose":55.04,"latestTime":"19:30 EDT","volume":20,"amount":1097.9053,"timestamp":1791588605643,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.5470859158871705,"impliedVol":0.3943,"impliedVolPercentile":0.996},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SBIO\",,,,,undefined,":{"symbol":"SBIO","floatShares":3500000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.5470859158871705,"shares":3500000,"dividePrice":0,"high":55.5141,"amplitude":0.021301,"preClose":53.945,"low":54.365,"week52Low":40.4,"pbRate":"--","week52High":70.85,"institutionHeld":0,"latestPrice":55.04,"eps":0,"divideRate":0,"volume":33639,"delay":0,"ttmEps":0,"open":54.5,"prevYearClose":51.22,"prevWeekClose":56.15,"prevMonthClose":58.3,"prevQuarterClose":58.3,"fiveDayClose":56.15,"twentyDayClose":63.29,"sixtyDayClose":63.44},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SBIO\",params:#limit:5,,,undefined,":[{"date":"2024-12-19","symbol":"SBIO","amount":1.17346,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-19","defaultRemindTime":1734618600000,"name":"ALPS Medical Breakthroughs ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-26","payableDate":"2024-12-19","currency":"USD","dateTimestamp":1734584400000,"payDate":"2024-12-26"},{"date":"2023-12-21","symbol":"SBIO","amount":0.07106,"announcedDate":"2023-12-20","type":"dividend","market":"US","newRecordDate":"2023-12-22","defaultRemindTime":1703169000000,"name":"ALPS Medical Breakthroughs ETF","recordDate":"2023-12-27","payableDate":"2023-12-22","currency":"USD","dateTimestamp":1703134800000,"payDate":"2023-12-27"},{"market":"US","date":"2019-12-19","symbol":"SBIO","amount":0.01585,"name":"ALPS Medical Breakthroughs ETF","recordDate":"2019-12-27","payableDate":"2019-12-20","currency":"USD","type":"dividend","dateTimestamp":1576731600000},{"market":"US","date":"2018-12-20","symbol":"SBIO","amount":0.78406,"name":"ALPS Medical Breakthroughs ETF","recordDate":"2018-12-27","payableDate":"2018-12-21","currency":"USD","type":"dividend","dateTimestamp":1545282000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SBIO\",market:\"US\",,,undefined,":[{"executeDate":"2018-12-20","recordDate":"2018-12-21","paymentDate":"2018-12-27","value":0.78406,"currency":"USD"},{"executeDate":"2019-12-19","recordDate":"2019-12-20","paymentDate":"2019-12-27","value":0.01585,"currency":"USD"},{"executeDate":"2023-12-21","recordDate":"2023-12-22","paymentDate":"2023-12-27","value":0.07106,"currency":"USD"},{"executeDate":"2024-12-19","recordDate":"2024-12-19","paymentDate":"2024-12-26","value":1.17346,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SBIO\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SBIO\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2656585399","title":"Xenon Pharma Grants 32,758 Inducement Stock Options, 19,013 RSUs to New Hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2656585399","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656585399?lang=en_us&edition=fundamental","pubTime":"2026-08-01 04:01","pubTimestamp":1785528080,"startTime":"0","endTime":"0","summary":"Xenon Pharma grants 32,758 inducement stock options, 19,013 RSUs to new hiresXenon Pharmaceuticals granted inducement equity awards to 11 new non-officer employees, totaling 32,758 share options and 1","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDLbfcL3N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","IE00BGHQF748.EUR","BK4112","IBRN","BK4139","LU2210149790.SGD","BK4585","SG9999014013.SGD","XENE","IE00BKPKM429.USD","LU0314104364.USD","SG9999014021.USD","IE00B3QW5Z07.USD","BK4588","BCDF","NDAQ","SBIO","IE00BN0W2T93.GBP","SG9999014005.SGD","SG9999014039.USD","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","LU2210150020.SGD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656399370","title":"Xenon Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2656399370","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656399370?lang=en_us&edition=fundamental","pubTime":"2026-08-01 04:01","pubTimestamp":1785528060,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nTUA7BSC6X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XENE","IBRN","BK4139","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656391209","title":"Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2656391209","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656391209?lang=en_us&edition=fundamental","pubTime":"2026-08-01 04:01","pubTimestamp":1785528060,"startTime":"0","endTime":"0","summary":"VANCOUVER, BC and BOSTON, MA, July  31, 2026  (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical deve","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/31/3337042/33485/en/Xenon-Pharmaceuticals-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCLG","SBIO","BK4139","IBRN","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656393679","title":"Sector Update: Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2656393679","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656393679?lang=en_us&edition=fundamental","pubTime":"2026-08-01 00:57","pubTimestamp":1785517053,"startTime":"0","endTime":"0","summary":"Healthcare stocks declined Friday afternoon, with the NYSE Healthcare Index shedding 0.8% and the State Street Health Care Select Sector SPDR ETF  decreasing 0.5%.The iShares Biotechnology ETF  fell 2.2%.In corporate news, AbbVie  lowered its full-year earnings guidance on Friday to account for the expected dilution from its planned acquisition of Apogee Therapeutics , despite reporting stronger-than-expected Q2 results. AbbVie shares were down 2%.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE0004445239.USD","SBIO","AGNG","IE00BLSP4452.SGD","LABU","BK4534","LU0868494708.USD","LU2129689605.HKD","PPH","XBI","GLAM","LU0198837287.USD","XLV","BK4581","SG9999015986.USD","IE00BFTCPJ56.SGD","VHT","FTXH","LU0058720904.USD","TRUH","IYH","LU0395794307.EUR","MEDX","ABBV","LU0965509010.AUD","FHLC","HCSG","LU0124676726.USD","IXJ","PJP","LU1732800096.USD","LU2237443978.SGD","LU2237443622.USD","RXL","JDOC","IE00B2B36J28.USD","LU0949170772.SGD","IBB","IE0002141913.USD","LU0289739699.SGD","LU0320765646.SGD","LU1093756325.SGD","SG9999001440.SGD","LU1023059063.AUD","APGE","LU0128525929.USD","LU0310800379.SGD","IE0009355771.USD","LU0029864427.USD","LU1244550494.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655293366","title":"AbbVie Lowers Outlook to Account for Acquisition, as 2Q Profit Jumps","url":"https://stock-news.laohu8.com/highlight/detail?id=2655293366","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655293366?lang=en_us&edition=fundamental","pubTime":"2026-07-31 20:27","pubTimestamp":1785500820,"startTime":"0","endTime":"0","summary":"AbbVie lowered its full-year adjusted earnings outlook to account for its acquisition of Apogee Therapeutics, as the company logged higher profit and revenue in the recent quarter.The pharmaceutical c","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1670628061.USD","SG9999015978.USD","LU2357627491.SGD","GXDW","LU0511384066.AUD","LU1934455863.HKD","PMDE","TRUH","DECU","JDOC","SG9999011175.SGD","LU2237443465.HKD","VHT","LU1037948897.HKD","RXL","FEBU","ABBV","IYH","MEDX","IXJ","IE00BVYPNV92.GBP","IE0002141913.USD","AGNG","LU0256863811.USD","PPH","APGE","LU1023059063.AUD","FHLC","LU1732799900.SGD","GLAM","SBIO","LU0456855351.SGD","LU0417517546.SGD","PJP","JOYT","VOTE","IE00BGHQF631.EUR","LU0170899867.USD","LU0965509283.SGD","LU1291159041.SGD","LU0708994859.HKD","VGFPF","LU1989772840.SGD","BK4550","RGLO","LU1585245621.USD","XLV","FTXH","IE00B19Z3581.USD","LU0057025933.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655656163","title":"Abbvie Shares Down 3.6% Premarket After Co Cuts 2026 Profit Forecast on Apogee Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2655656163","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655656163?lang=en_us&edition=fundamental","pubTime":"2026-07-31 19:50","pubTimestamp":1785498658,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nL4N43X1CJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2347655156.SGD","BK4559","PPH","LU0456855351.SGD","IE000MB6IJN5.SGD","LU2087621335.USD","LU1732800096.USD","SBIO","LU1061106388.HKD","JDOC","AGNG","LU1551013425.SGD","LU1718418525.SGD","LU2129689431.USD","MEDX","LU2089984988.USD","RXL","LU0689626769.HKD","LU0203347892.USD","LU0820561909.HKD","LU1670628061.USD","LU1839511570.USD","VHT","BK4588","IXJ","LU0170899867.USD","FHLC","FTXH","IE0002141913.USD","TRUH","SG9999015945.SGD","LU0211328371.USD","SG9999001440.SGD","IE00B19Z3B42.SGD","ABBV","LU1037948541.HKD","IE000BZT7R73.USD","LU0738911758.USD","IYH","IE00BVYPNW00.USD","LU0965509283.SGD","GLAM","SG9999015952.SGD","XLV","LU0689472784.USD","IE00BFTCPJ56.SGD","LU0122379950.USD","PJP","APGE","IE00BSNM7G36.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655655533","title":"AbbVie Trims 2026 Profit Forecast on Apogee Buy, Beats Second-quarter Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2655655533","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655655533?lang=en_us&edition=fundamental","pubTime":"2026-07-31 19:48","pubTimestamp":1785498512,"startTime":"0","endTime":"0","summary":"AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimatesJuly 31 (Reuters)-AbbVieABBV.Non Friday trimmed its 2026 profit forecast to account for its planned Apogee Therapeutics a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nL4N43X0YB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PJP","LU1989772923.USD","LU2237443465.HKD","LU0912757837.SGD","IYH","LU1037948541.HKD","LU0868494708.USD","IE00BBT3K403.USD","LU0170899867.USD","LU1934455277.USD","LU0456855351.SGD","LU0320765646.SGD","LU0114720955.EUR","LU0859254822.USD","LU1162221912.USD","IE00BVYPNW00.USD","FTXH","SBIO","TRUH","APGE","LU1983299246.USD","LU0256863811.USD","MEDX","PPH","LU2112291526.USD","AGNG","BK4534","XLV","LU0289961442.SGD","FHLC","LU2089283258.USD","IE00BJT1NW94.SGD","LU2237443978.SGD","LU1003077747.HKD","IXJ","VHT","LU0965509101.SGD","IE000SO60NU8.SGD","LU1496350502.SGD","LU1989771016.USD","LU2089284900.SGD","LU0158827948.USD","JDOC","LU1267930573.SGD","IE00BLSP4239.USD","GLAM","RXL","BK4550","ABBV","LU0203347892.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655800214","title":"Health Rounds: Experimental Cell Therapy Slows Heart Failure Progression in Duchenne Muscular Dystrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2655800214","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655800214?lang=en_us&edition=fundamental","pubTime":"2026-07-31 02:55","pubTimestamp":1785437705,"startTime":"0","endTime":"0","summary":"Health Rounds: Experimental cell therapy slows heart failure progression in Duchenne muscular dystrophyJuly 30 -Hello Health Rounds readers!","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nL1N43W1BF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAPR","CGON","SBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654885962","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Phibro Animal Health (PAHC), Universal Health (UHS) and CG Oncology, Inc. (CGON)","url":"https://stock-news.laohu8.com/highlight/detail?id=2654885962","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654885962?lang=en_us&edition=fundamental","pubTime":"2026-07-28 23:20","pubTimestamp":1785252006,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Phibro Animal Health (PAHC), Universal Health (UHS...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-phibro-animal-health-pahc-universal-health-uhs-and-cg-oncology-inc-cgon-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-phibro-animal-health-pahc-universal-health-uhs-and-cg-oncology-inc-cgon-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","CG","BK4135","GPZ","PAHC","LABU","BK4581","XBI","LU0128526141.USD","SBIO","XLV","UHS","LU0029874061.USD","BK4585","BK4588","HCSG","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","BK4007","CGON","BK4139","BK4185","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654002626","title":"CG Oncology announces publication of BOND-003 results in The Lancet Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2654002626","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654002626?lang=en_us&edition=fundamental","pubTime":"2026-07-28 06:50","pubTimestamp":1785192608,"startTime":"0","endTime":"0","summary":"CG Oncology (CGON) announced the publication of results from the pivotal Phase 3 BOND-003 Cohort C trial evaluating cretostimogene grenadenorepvec ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cg-oncology-announces-publication-of-bond-003-results-in-the-lancet-oncology-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cg-oncology-announces-publication-of-bond-003-results-in-the-lancet-oncology-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4135","BK4139","CG","BK4585","IE00BGHQF748.EUR","BK4588","IE00B3QW5Z07.USD","SBIO","CGON","IE00B64PRP62.GBP","GPZ","BOND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654302613","title":"CG Oncology Says Phase 3 Bond-003 Data for Cretostimogene in BCG-unresponsive Bladder Cancer Publish in Lancet Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2654302613","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654302613?lang=en_us&edition=fundamental","pubTime":"2026-07-28 06:46","pubTimestamp":1785192363,"startTime":"0","endTime":"0","summary":"CG Oncology says Phase 3 BOND-003 data for cretostimogene in BCG-unresponsive bladder cancer publish in Lancet OncologyCG Oncology reported publication of pivotal Phase 3 BOND-003 Cohort C results in ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nNDL6LLX4c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","SG9999014013.SGD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","LU2095319765.USD","SBIO","BK4585","IE00B64PRP62.GBP","SG9999014005.SGD","CGON","LU2210149790.SGD","NDAQ","BK4112","LU0314104364.USD","IE00BKPKM429.USD","BK4588","IE00BGHQF748.EUR","SG9999014039.USD","IE00BN0W2V16.EUR","SG9999014021.USD","BCDF","LU2210150020.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654045069","title":"Oppenheimer would own Capricor Therapeutics into committee meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2654045069","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654045069?lang=en_us&edition=fundamental","pubTime":"2026-07-27 22:20","pubTimestamp":1785162008,"startTime":"0","endTime":"0","summary":"After briefing documents for this Wednesday’s FDA advisory committee for deramiocel became available this morning, Oppenheimer analyst Leland Gersh...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oppenheimer-would-own-capricor-therapeutics-into-committee-meeting-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oppenheimer-would-own-capricor-therapeutics-into-committee-meeting-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","XBIX","BK4139","BBH","BK4588","FBT","IBRN","CAPR","SBIO","PBE","BK4127","BBP","OPY","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652280730","title":"CG Oncology Director Leonard Post Disposes of 1,000 Shares for $71,170","url":"https://stock-news.laohu8.com/highlight/detail?id=2652280730","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652280730?lang=en_us&edition=fundamental","pubTime":"2026-07-18 04:15","pubTimestamp":1784319335,"startTime":"0","endTime":"0","summary":"CG Oncology director Leonard Post disposes of 1,000 shares for $71,170CG Oncology director Leonard E. Post sold 1,000 common shares on July 15 at USD 71.17, cutting his direct stake to zero.Post also ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260717:nNDL9wLLGG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"CG Oncology Director Leonard Post Disposes of 1,000 Shares for $71,170","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGON","SBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652209194","title":"Ani Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter","url":"https://stock-news.laohu8.com/highlight/detail?id=2652209194","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652209194?lang=en_us&edition=fundamental","pubTime":"2026-07-17 06:33","pubTimestamp":1784241232,"startTime":"0","endTime":"0","summary":"July 16 (Reuters) - ANI Pharmaceuticals Inc::*ANI PHARMACEUTICALS ANNOUNCES INTENT TO APPEAL RULINGS IN CG ONCOLOGY MATTER*ANI PHARMACEUTICALS - TRIAL COURT DENIES ANI PHARMACEUTICALS' MOTION FOR NEW ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nRSD9341tC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGON","BK4139","SBIO","LU1559883803.SGD","LU0566484027.USD","BK4007","ANIP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652342763","title":"Why Healthcare Stocks Look Like a Haven in This Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2652342763","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652342763?lang=en_us&edition=fundamental","pubTime":"2026-07-17 05:07","pubTimestamp":1784236020,"startTime":"0","endTime":"0","summary":"Healthcare has outperformed the market over the past three months, thanks to promising biopharma developments and improved sentiment on large insurers, particularly those that serve seniors in the Med","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","LU2456880835.USD","AGNG","FTXO","IE0009355771.USD","LU1548497426.USD","FHLC","IAI","LU0820561818.USD","XBI","BK4516","LU0057025933.USD","LU0267386448.USD","FTXH","XLV","HCSG","LU0965509283.SGD","LU0158827781.USD","LU1732799900.SGD","LU1791710400.SGD","BK4585","ABBV","BK4581","LU0289961442.SGD","LU1074936037.SGD","IE00BSNM7G36.USD","PJP","JDOC","LU1668664300.SGD","MEDX","LU0114720955.EUR","RXL","LABU","LU0545039389.USD","IXJ","PPH","KBWB","IYH","VHT","LU0198837287.USD","LU0225283273.USD","APGE","LU1923622614.USD","SBIO","IYF","LU0511384066.AUD","BK4137","LU0882574055.USD","SG9999011175.SGD","LU1244550494.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652427187","title":"ANI Pharmaceuticals intends to appeal rulings in CG Oncology matter","url":"https://stock-news.laohu8.com/highlight/detail?id=2652427187","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652427187?lang=en_us&edition=fundamental","pubTime":"2026-07-17 04:40","pubTimestamp":1784234411,"startTime":"0","endTime":"0","summary":"ANI Pharmaceuticals (ANIP) announced that Judge Sheldon K. Rennie, on July 16, denied ANI’s post-trial motions for a new trial and judgment as a ma...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ani-pharmaceuticals-intends-to-appeal-rulings-in-cg-oncology-matter-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ani-pharmaceuticals-intends-to-appeal-rulings-in-cg-oncology-matter-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4135","IE00B3QW5Z07.USD","LU1559883803.SGD","CG","SBIO","BK4139","CGON","LU0566484027.USD","ANIP","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652422960","title":"ANI Pharma Plans Delaware Supreme Court Appeal in CG Oncology Dispute","url":"https://stock-news.laohu8.com/highlight/detail?id=2652422960","media":"Reuters","labels":["shareholding","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652422960?lang=en_us&edition=fundamental","pubTime":"2026-07-17 04:34","pubTimestamp":1784234069,"startTime":"0","endTime":"0","summary":"ANI Pharma plans Delaware Supreme Court appeal in CG Oncology disputeANI Pharmaceuticals will appeal to the Delaware Supreme Court after a trial judge denied its post-trial motions in a dispute with C","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nNDL9M2TVg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014005.SGD","SG9999014021.USD","LU2095319765.USD","LU2210149790.SGD","LU0566484027.USD","SG9999014013.SGD","LU1559883803.SGD","BK4585","BCDF","BK4007","IE00BN0W2V16.EUR","ANIP","IE00BN0W2W23.USD","IE00B64PRP62.GBP","BK4139","CGON","LU2210150020.SGD","IE00BN0W2T93.GBP","BK4112","LU0314104364.USD","SBIO","IE00BGHQF748.EUR","BK4588","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651948960","title":"CG Oncology Director James Mulay Disposes of Common Shares Worth $1.82 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2651948960","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651948960?lang=en_us&edition=fundamental","pubTime":"2026-07-15 04:15","pubTimestamp":1784060148,"startTime":"0","endTime":"0","summary":"CG Oncology director James Mulay disposes of common shares worth $1.82 millionCG Oncology director James Mulay exercised director stock options for 24,165 common shares at $26.63 on July 10, 2026.Mula","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nNDL6YPf6w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"CG Oncology Director James Mulay Disposes of Common Shares Worth $1.82 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGON","SBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651486763","title":"Press Release: $hareholder Alert: the M&A Class Action Firm Launches Legal Inquiry for the Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2651486763","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651486763?lang=en_us&edition=fundamental","pubTime":"2026-07-15 04:00","pubTimestamp":1784059200,"startTime":"0","endTime":"0","summary":"NEW YORK, July 14, 2026 /PRNewswire/ --Class Action Attorney Juan Monteverde with Monteverde & Associates PC , has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating-- Corebridge Financial, Inc.   related to its merger with. Equitable Holdings, Inc. Upon closing of the proposed transaction,Corebridge shareholders will own approximately 51% of the combined. Brokerage Inc. Under the terms of the proposed transaction, RE/MAX. About Monteverde & Associates PCOur firm litigates and has recovered money for shareholders...and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court.No company, director or officer is above the law. If you own common stock in the above listed compan","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","LU2456880835.USD","APGE","BK4534","LU0203347892.USD","LU1162221912.USD","LU2125154778.USD","LU0130518102.USD","LU0072461881.USD","LU1506573853.SGD","LU0098860793.USD","LU1201861249.SGD","LU0477156797.USD","PEVC","CUL3","LU1244550221.USD","LU1791807156.HKD","LU0320765646.SGD","LU1267930227.SGD","LU0130103400.USD","LU0128525689.USD","BK4585","LU2360032135.SGD","FTXO","LU1244550577.SGD","BK4504","CRBG","LU0053671581.USD","LU0130517989.USD","LU0314106906.USD","LU2236285917.USD","SBIO","IE00B19Z3581.USD","BK4207","LU0162691827.USD","BK4184","LU0106831901.USD","IYF","BK4225","LU2462157665.USD","LU0980610538.SGD","LU0170899867.USD","BK4588","GBCS","LU1244550494.USD","IE00BSNM7G36.USD","BK4139","RMAX","BK4079","LU0130102774.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651281147","title":"CG Oncology (CGON) In Focus Following Early Trial Results And BLA Timing Questions On Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2651281147","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651281147?lang=en_us&edition=fundamental","pubTime":"2026-07-14 06:24","pubTimestamp":1783981455,"startTime":"0","endTime":"0","summary":"Early trial results and BLA timeline put CG Oncology in focus\nCG Oncology (CGON) is back in the spotlight after positive early Phase II data for cretostimogene grenadenorepvec with gemcitabine and clearer timing for a planned biologics license application in high-risk bladder cancer.\nSee our latest analysis for CG Oncology.\nThe recent early Phase II update and clearer BLA timeline appear to be feeding into sentiment around CG Oncology, with a 30-day share price return of 21.73% and a year to...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/cg-oncology-cgon-in-focus-following-early-trial-results-and","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/cg-oncology-cgon-in-focus-following-early-trial-results-and","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CG","BK4139","DCF","BK4135","SBIO","IE00BGHQF748.EUR","IE00B64PRP62.GBP","CGON","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":6,"totalSize":124,"code":"91000000","status":"200"}]}}